1941results about "Dipeptide ingredients" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

Provided is an antibody-drug conjugate for use in the treatment of cancer in which one or more KRAS mutants, particularly a KRAS G12V mutant, a KRAS G12D mutant, and a KRAS G12C mutant, are expressed. Also provided are a drug and a drug-linker conjugate for use in the antibody-drug conjugate.　The present inventors have produced an antibody-drug conjugate with which a heterocyclic compound represented by formula (II) and having an activity of inducing the decomposition of KRAS mutant proteins can be delivered to cancer in which EGFRs are expressed, the production being achieved by linking the compound to an anti-EGFR antibody. The present inventors have also discovered a drug-linker conjugate for use in the antibody-drug conjugate or a salt thereof. In cancer in which EGFRs are expressed, the antibody-drug conjugate induces the decomposition of one or more KRAS mutants, particularly a KRAS G12V mutant protein, a KRAS G12D mutant protein, and a KRAS G12C mutant protein, thereby inhibiting the KRAS mutants and exhibiting an anti-tumor effect.

Compounds disclosed herein or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

The present invention regards specific IBAT inhibitors useful in the prophylaxis and / or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.

The invention relates to a quinazoline compound as well as a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula (I) or pharmaceutically acceptable salt, stereoisomer, tautomer, polymorphic substance, solvate, N-oxide, isotope labeled compound, metabolite or prodrug thereof, and a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt, the stereoisomer, the tautomer, the polymorphic substance, the solvate, the N-oxide, the isotope labeled compound, the metabolite or the prodrug thereof. The invention also relates to a preparation method of the compound and application of the compound in preparation of drugs for preventing or treating KRAS G12D-mediated related diseases. # imgabs0 #

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and / or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

The invention provides an NSD protein degradation agent and application thereof, and particularly provides a compound with a structure as shown in a formula (I) or pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like in a targeted ubiquitination manner, so that the compound can be used for treating indications related to abnormal expression of the proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like. # imgabs0 #

The invention provides a whey protein deep hydrolysate with low sensitization and an allergy relieving effect as well as a preparation method and application of the whey protein deep hydrolysate. According to the method, the alkaline protease, the neutral protease and the glutamyltransferase are sequentially used for carrying out first enzymolysis, second enzymolysis and third enzymolysis on the whey protein raw material, and the whey protein hydrolysate which is low in molecular weight, good in taste, good in digestion and absorption performance, low in sensitization and capable of effectively relieving allergic reaction of the organism is obtained.

The present application relates to a compound or a pharmaceutically acceptable salt and / or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and / or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and / or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and / or killing target cells. For example, the compound includes a compound of Formula I

The invention discloses application of a lysosome cathepsin L inhibitor in a medicine for treating or relieving allergic airway inflammation, and relates to the field of allergic airway inflammation. It is found through research that inflammatory response of asthma can be relieved by inhibiting expression of lysosome CTSL in macrophages and animal models; the inflammatory response of asthma can be relieved by inhibiting expression of lysosome CTSL in macrophages by using a small-molecule inhibitor and myeloid specific knockout CTSL, so that the lysosome cathepsin L inhibitor can effectively relieve allergic airway inflammation, and a new direction can be provided for research and development of drugs for treating and relieving allergic airway inflammation in the future.

The present invention relates to the fields of medicine and cosmetology, and discloses a cell active peptide composition that promotes the regeneration of multi-type collagen structural proteins, its preparation method, and its application in medicine and cosmetology. The composition uses raw materials such as tripeptide-10 citrulline, hexapeptide-9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide-3, acetyl tetrapeptide-11, palmitoyl dipeptide-7, and palmitoyl pentapeptide-4. The composition can promote the coordinated expression of skin type I, type III, type IV, type VII, type XVII collagen, fibronectin, elastin, and glycosaminoglycans; prevent collagen cross-linking, maintain triple helix structure, and inhibit collagen degradation. Applied to dermatology and cosmetology, it can accelerate the regeneration of structural proteins such as skin collagen, repair skin damage, reduce wrinkles such as crow's feet, tear groove lines, nasolabial folds, and under-eye lines, solve the skin aging problem caused by the loss of structural proteins such as collagen, and improve skin elasticity and firmness.

The invention provides a composition with a function of stabilizing skin enzyme activity as well as a preparation method and application of the composition, and the composition is prepared from the following components in parts by mass: 0.001 to 0.01 part of superoxide dismutase, 0.001 to 0.05 part of nicotinamide adenine dinucleotide, 0.11 to 12 parts of a polypeptide compound a and 0.005 to 0.5 part of a polypeptide compound b. The invention also provides a preparation method of the composition and application of the composition in preparation of skin care products for improving skin enzyme activity, repairing skin and resisting aging. The composition can be prepared into emulsion, solution, paste, gel or spray. The composition can effectively improve the enzyme activity of skin, improve the texture and appearance of the skin and repair the skin, and is beneficial to delaying the aging of the skin at the same time.

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.

The invention relates to the field of bacteriostatic cream, and particularly discloses skin bacteriostatic cream and a preparation method thereof. The skin antibacterial cream is prepared from the following raw materials in parts by weight: 4 to 6 parts of bran coat extract, 2 to 4 parts of chlorhexidine salt, 2 to 4 parts of rutin extract, 1 to 3 parts of carnosine, 0.5 to 0.8 part of sodium hyaluronate, 0.8 to 1.2 parts of film-forming agent and 5 to 8 parts of purified water. The preparation method comprises the following steps: mixing the film-forming agent and a part of water, and uniformly stirring to obtain a film-forming agent solution; the preparation method comprises the following steps: mixing sodium hyaluronate and water, heating, stirring until the sodium hyaluronate and the water are completely dissolved, adding the cavings extract, the rutin extract, the chlorhexidine salt and the carnosine, stirring until the mixture is uniformly dispersed, heating to 75-85 DEG C, emulsifying for 25-35 minutes, homogenizing, adding a film-forming agent solution into the homogenized emulsion, and stirring, concentrating, degassing and discharging the paste in vacuum to obtain the antibacterial paste. The composition can be used for diminishing inflammation and resisting bacteria of damaged skin, and has the advantages of being high in antibacterial rate and capable of avoiding skin pigmentation.

The invention discloses a sulfatase-driven polypeptide condensate with a chemotherapy sensitization effect and a preparation method thereof, and belongs to the field of biological medicines. According to the principle that sulfatase can catalyze hydrolysis of sulfate bonds, main polypeptide YSO4F responded by sulfatase enzyme is designed and synthesized; and the enzyme response aggregate m-YSO4F-LSG is blended with a protein G3BP2 ligand FGDF-YSO4F to prepare the enzyme response aggregate m-YSO4F-LSG with a sorafenib chemosensitization effect. Tumor cells can generate stress particles with a chemotherapy drug resistance effect under the stimulation of a chemotherapy drug sorafenib, the treatment effect of the sorafenib is weakened, and the protein G3BP2 is one of core proteins of the stress particles. After the m-YSO4F-LSG enters tumor cells, sulfate groups are hydrolyzed under the catalytic action of sulfatase overexpressed in tumor cell lysosomes, so that phase separation liquid drops d-YF-LSG with high affinity to protein G3BP2 are formed in the cells in situ, the phase separation liquid drops d-YF-LSG act with the protein G3BP2 and are fused with stress particles, chemotherapy drug resistance generated by the stress particles is inhibited, and the chemotherapy effect is improved. The treatment effect is improved.

The present invention relates to compounds having antidiabetic activity, their preparation methods and uses. The compounds are analogues of diprotin A, have strong antidiabetic activity, belong to DPP-IV inhibitors, can improve blood insulin levels, and open up a new way for the treatment of diabetes. Applying the compounds to the preparation of foods, health products and drugs for preventing and / or treating diabetes has high social value and great significance.

The invention relates to the technical field of pharmaceutical preparations, in particular to a stable perindopril amlodipine tablet and a preparation method thereof, and the tablet comprises the following components in percentage by weight: 5.0% of arginine perindopril; 3.5% of amlodipine besylate; 20%-40% of pregelatinized starch; 40%-68% of a microcrystalline cellulose colloidal silicon dioxide compound; 2.5%-6% of a disintegrating agent, wherein the disintegrating agent is selected from one or more of ion exchange resin, sodium alginate and croscarmellose sodium; the pregelatinized starch and the microcrystalline cellulose colloidal silicon dioxide compound are selected as main diluents, so that the Maillard reaction possibly occurring between the lactose and the active pharmaceutical ingredients is completely avoided, the problem of increase of related substances is fundamentally solved, and the stability and the safety of the product are remarkably improved.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein, such as a cytokine. In various embodiments, the disclosure also provides for the treatment of a disease or condition (e.g., a disease or disorder) using an agent comprising and / or modulating the expression or activity of an immunomodulatory-related protein. The present invention relates to methods for identifying such agents (e.g., diseases or conditions associated with whole genome association studies (GWAS), cancer genome maps (TCGA), whole genome sequencing, whole phenotype group association studies (PheWAS), expression quantitative trait locus (eQTL) studies, or combinations thereof), and methods for identifying such agents.

The invention discloses a compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a compound which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The compound provided by the invention provides a new scheme for treating lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The invention discloses a long-acting anti-aging composition capable of quickly removing dark circles and application of the composition. The composition is prepared from the following components: beta-nicotinamide mononucleotide, glutathione, acetyl hexapeptide-8, acetyl tetrapeptide-5, snake venom-like peptide, arginine / lysine polypeptide, tocopheryl acetate and ergothioneine. According to the present invention, multiple functions are adopted, such that the effects of dark circle removing, repair, elasticity recovery, aging resistance and the like are provided so as to block the generation of dark circle, and the normal function of skin is ensured. The composition disclosed by the invention has the effect of quickly removing dark circles, and when the eye cream contains the composition, the eye cream can effectively remove the dark circles and has an obvious and quick effect within 15 minutes; after being used for a long time, the eye mask can remove dark circles and play a good control role.

The invention provides an application of bortezomib in preparation of an anti-avian influenza virus drug. The bortezomib has the application of inhibiting the activity of avian influenza virus H7N9 neuraminidase. Researches show that the bortezomib can be combined with neuraminidase, the virtual calculation activity IC50 based on calculation is 3.37 * 10 <-7 > mol / L, the bortezomib can reduce the activity of neuraminidase, and the IC50 is 35.561 mu M; the bortezomib can inhibit the replication and propagation of avian influenza H7N9, and the IC50 is 0.043 [mu] M. In a word, the bortezomib has obvious activity of inhibiting neuraminidase of the avian influenza virus H7N9 and has the application of resisting the avian influenza virus.

Disclosed in the present invention is a compound represented by formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof. Such a PSMA compound has higher tumor uptake and / or lower or substantially equivalent kidney uptake, can improve the drug targeting effect and / or reduce the kidney injury risk, and is conducive to better meeting the medication needs of patients.

To provide a composition and a pharmaceutical composition each of which exhibits, while suppressing rapid degeneration of tissues caused by administration thereof, excellent regulatory activity for chemokine receptors and excellent medicinal effects on a posterior eye disease and the like.SOLUTION: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising the composition.SELECTED DRAWING: None

The present invention regards specific IBAT inhibitors useful in the prophylaxis and / or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.

The invention belongs to the field of biological medicines, particularly relates to an oral polypeptide composition system capable of being stably absorbed in gastrointestinal tracts, and particularly discloses an oral polypeptide composition which comprises polypeptide molecules (A), a surfactant (B) and an amino acid single-molecule or double-molecule combination (C), the molecular weight of the peptide medicine used as the medicine in the oral polypeptide composition is in the range of 0.1 kDa to 20 kDa. The acting part of the composition system is small intestine or large intestine; the stability and absorbability of the polypeptide composition in gastrointestinal tracts are obviously improved and enhanced.

Provided are a symbiotic composition, a metabolite, and uses thereof for preventing and treating obesity-related diseases. A symbiotic composition comprising lychee polyphenols, Bifidobacterium longum, and methionine. Also provided is a symbiotic composition for preventing and treating obesity-related diseases. Also provided is a metabolite for preventing and treating obesity-related diseases.